We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-19.4%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.07B
AUM Growth
-$277M
(-12%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
9.83%
Top 10 Holdings %
Top 10 Hldgs %
48.47%
Holding
98
New
23
Increased
27
Reduced
24
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$50.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$48.9M |
| 3 |
SHPG
Shire pic
SHPG
|
+$40.3M |
| 4 |
CELG
Celgene Corp
CELG
|
+$33.1M |
| 5 |
Amgen
AMGN
|
+$26.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$57.3M |
| 2 |
Halozyme
HALO
|
+$36M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$31.7M |
| 4 |
United Therapeutics
UTHR
|
+$30.6M |
| 5 |
Merck
MRK
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADPT
26
DELISTED
Adeptus Health Inc
ADPT
| $24.7M | 1.19% |
444,783
+257,039
| +137% | +$13.3M |
|
|
NXTM
27
DELISTED
NxStage Medical Inc.
NXTM
| $24.7M | 1.19% |
1,647,309
+946,006
| +135% | +$15.9M |
|
28
Acadia Healthcare
ACHC
$3.17B
| $23.1M | 1.12% |
418,805
+259,953
| +164% | +$14.8M |
|
29
UnitedHealth
UNH
$383B
| $22.6M | 1.09% |
175,590
-34,058
| -16% | -$4.03M |
|
|
ADXS
30
DELISTED
Advaxis Inc
ADXS
| $19.6M | 0.95% |
144,934
+25,553
| +21% | +$2.83M |
|
31
Acadia Pharmaceuticals
ACAD
$4.3B
| $19.3M | 0.93% |
+690,700
| New | +$15.1M |
|
|
STJ
32
DELISTED
St Jude Medical
STJ
| $18.4M | 0.89% |
334,584
-62,577
| -16% | -$3.41M |
|
|
SGNT
33
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| $18.3M | 0.88% |
1,501,296
+690,934
| +85% | +$9.69M |
|
34
Ionis Pharmaceuticals
IONS
$8.75B
| $17.5M | 0.85% |
433,300
+283,300
| +189% | +$11.5M |
|
35
uniQure
QURE
$2.73B
| $17M | 0.82% |
1,427,313
+288,800
| +25% | +$4.26M |
|
36
PTC Therapeutics
PTCT
$6.47B
| $16.8M | 0.81% |
2,615,241
+1,028,983
| +65% | +$17.9M |
|
37
Prothena Corp
PRTA
$454M
| $16.4M | 0.79% |
+398,100
| New | +$15.6M |
|
|
ISEE
38
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $15.1M | 0.73% |
357,106
+68,200
| +24% | +$3.47M |
|
39
Intuitive Surgical
ISRG
$125B
| $14M | 0.68% |
210,303
-68,967
| -25% | -$4.27M |
|
|
SAGE
40
DELISTED
Sage Therapeutics
SAGE
| $13.5M | 0.65% |
+421,084
| New | +$14.8M |
|
|
AIMT
41
DELISTED
Aimmune Therapeutics
AIMT
| $13.3M | 0.64% |
982,133
| – | – |
|
42
TG Therapeutics
TGTX
$8.26B
| $13M | 0.63% |
1,521,667
| – | – |
|
|
NVO
43
Novo Nordisk
NVO
$219B
| $11.7M | 0.57% |
432,350
-121,800
| -22% | -$3.26M |
|
|
TMH
44
DELISTED
Team Health Holdings Inc
TMH
| $11.2M | 0.54% |
+269,000
| New | +$11M |
|
|
IMDZ
45
DELISTED
Immune Design Corp.
IMDZ
| $11.1M | 0.54% |
856,867
| – | – |
|
46
Edwards Lifesciences
EW
$48.9B
| $9.75M | 0.47% |
331,623
-419,262
| -56% | -$11.6M |
|
47
Teladoc Health
TDOC
$1.74B
| $9.37M | 0.45% |
975,533
+398,172
| +69% | +$5.65M |
|
48
Novartis
NVS
$285B
| $8.97M | 0.43% |
138,166
-60,934
| -31% | -$4.15M |
|
|
AVXS
49
DELISTED
AveXis, Inc. Common Stock
AVXS
| $8.11M | 0.39% |
+297,600
| New | +$6.5M |
|
|
NUVA
50
DELISTED
NuVasive, Inc.
NUVA
| $8.09M | 0.39% |
+166,300
| New | +$7.55M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q1 2016 Portfolio in Review
As of Q1 2016, Sectoral Asset Management held 98 positions worth $2.07B, down 12% from $2.35B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Sectoral Asset Management deployed $203M of net new capital in Q1 2016, opening 23 new positions and adding to 27 existing holdings. Its largest new stake was Portola Pharmaceuticals, Inc.: 1,593,039 shares worth $32.5M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier.
On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $31.7M trimmed.
- Sectoral Asset Management's largest Q1 2016 buy was Portola Pharmaceuticals, Inc.: 1,593,039 shares worth $32.5M.
- Sectoral Asset Management added most to Neurocrine Biosciences in Q1 2016, an estimated $48.9M increase.
- Sectoral Asset Management's biggest Q1 2016 reduction was Thermo Fisher Scientific, cutting an estimated $31.7M.
- Sectoral Asset Management fully exited Seagen Inc. Common Stock in Q1 2016, selling an estimated $57.3M.
- Sectoral Asset Management's ten largest holdings make up 48% of its $2.07B portfolio in Q1 2016.
- Sectoral Asset Management opened 23 new positions and closed 17 in Q1 2016.
- Sectoral Asset Management's portfolio value fell 12% quarter-over-quarter to $2.07B.
Based on Sectoral Asset Management's 13F filing for Q1 2016, filed 13 May 2016.